GLENMARK PHARMACEUTICALS LTD. - Outcome of Preferential Issue Committee Committee

Glenmark Pharmaceuticals Ltd has informed BSE that the Preferential Issue Committee of the Board of Directors of the Company, at its Meeting held on May 19, 2015 allotted 1,08,00,000 Equity Shares of the face value of Re. 1/- each at a price of Rs. 875 per equity share to Aranda Investments (Mauritius) Pte Ltd., on preferential basis in terms of Chapter VII of SEBI (ICDR) Regulations and the applicable sections of the Companies Act, 2013.